Page d'accueil  |  Aide  |  Effacer
Anglais  |  Français
 Rechercher  |  Catégories  |  Titres A-Z  |  Pays  |  Comparer pays  |  Index  
Etendre sommaire
Document complet
Dérouler chapitre
Préférences

fermer ce livreGuidelines to Antiretroviral Drug Therapy in Kenya (WHO; 2001; 78 pages)
Afficher le documentFOREWORD
Afficher le documentACKNOWLEDGMENT
ouvrir ce répertoire et afficher son contenuCHAPTER ONE: INITIATING ANTIRETROVIRAL THERAPY
fermer ce répertoireCHAPTER TWO: MONITORING AND CHANGING THERAPY
Afficher le document2.1 Surrogate markers
Afficher le document2.2 Resistance testing
Afficher le document2.3 How often should CD4 Cell Count and Viral Load be performed (Frequency)
Afficher le document2.4 Treatment failure
Afficher le document2.5 Reasons for non-adherence
Afficher le document2.6 Considerations for changing a failing regimen
Afficher le document2.7 Guidelines for changing an antiretroviral regimen for suspected drug failure
Afficher le document2.8 Potential options for changing therapy*
ouvrir ce répertoire et afficher son contenuCHAPTER THREE: PHARMACOTHERAPEUTICS OF ARVS
ouvrir ce répertoire et afficher son contenuCHAPTER FOUR: GUIDELINES FOR THE USE OF ANTIRETROVIRAL DRUGS IN PAEDIATRIC HIV INFECTION
ouvrir ce répertoire et afficher son contenuCHAPTER FIVE: MANAGEMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTED PREGNANT WOMEN AND PREVENTION OF MOTHER TO CHILD TRANSMISSION (MTCT) OF HIV
ouvrir ce répertoire et afficher son contenuCHAPTER SIX: SPECIAL CONSIDERATIONS
ouvrir ce répertoire et afficher son contenuCHAPTER SEVEN: WHEN TO STOP TREATMENT (INTERRUPTIONS)
ouvrir ce répertoire et afficher son contenuCHAPTER EIGHT: GUIDELINES FOR POST EXPOSURE PROPHYLAXIS
Afficher le documentCHAPTER NINE: ACCESS TO DRUGS IN KENYA
ouvrir ce répertoire et afficher son contenuAPPENDICES
Afficher le documentBACK COVER
 

2.8 Potential options for changing therapy*

Reasons for change

Change

Toxicity or intolerance HIV
RNA suppressed below target

Change the offending drug (if discernible)

HIV RNA suppressed but still above target
And fewer than 8-16 weeks with therapy.

Change offending drug if discernible

HIV RNA above target, more than 8-16 weeks

Change entire regimen

Difficulty with adherence
HIV RNA suppressed below target, but adherence problems present

Change to simplified regimen with equal potency; substitute single drug if known

HIV RNA above target, more than 8-16 weeks with therapy.

Change to simplified regimen with equal potency substitute single drug if known.

HIV RNA above target, more than 8-16 weeks with therapy or prior successes.

Change entire regimen

Virologic failure adherence,
Failure to reach target viral load within adherence 8-16, weeks of therapy

Continue current regimen, assess consider intensification.

Failure to reach target viral load within 24-36 weeks of therapy

Change entire regime

Prior success but now confirmed drug faiture.

Change entire regime

Possible Regimens for patients who have failed initial Antiretroviral Therapy:

Possible Second line Regimens for Treatment Failure

• Following AZT/3TC/NFV

- d4T/ddl/EFZ or
- d4T/ddl/LPV or
- d4T/ddl/IDV


• Following AZT/3TC/EFZ(or NVP)

- d4T/ddl/NFV or
- d4T/ddl/LPV,


• Following AZT/3TC/NFV

- d4T/ddl/EFZ or
- d4T/ddl/LPV or
- d4T/ddl/IDV


Prior Regimen

 

New Regimen (Not listed in priority order)

2 NRTIs +

 

2 new NRTIs

 

Nelfinavir

RTV; IDV; or SQV + RTV; or NNRTI + RTV; or NNRTI ID**

 

Ritonavir

SQV + RTV**; NFV + NNRTI; or NFV + SQV

 

Indinavir

SQV + RTV; NFV + SQV

 

Saquinavir

RTV + SQV; OR NNRTI + IDV RTV + IDV

2 NRTIs + NNRTI

 

2 new NRTIs + a protease inhibitor

2 NRTIs

 

2 new NRTIs + a protease inhibitor

   

2 new NRTIs + RTV + SQV

   

1 new NRTI + 1 NNRTI + a protease inhibitor

   

2 protease inhibitors + NNRTI

1 NRTI

 

2 new NRTIs + a protease inhibitor

   

2 new NRTIs + NNRTI

   

1 new NRTI + 1 NNRTI + a protease inhibitor

These alternative combinations are still being studied in clinical trials and will be amended as more information is published.

vers la section précédentevers la section suivante

S'il vous plaît envoyez vos commentaires Anglais  |  Français